HIV-1 reverse transcriptase and protease mutations for drug-resistance detection among treatment-experienced and naïve HIV-infected individuals

Abstract

Background: The presence of drug resistance mutations (DRMs) against antiretroviral agents is one of the main concerns in the clinical management of individuals with human immunodeficiency virus-1 (HIV-1) infection, especially in regions of the world where treatment options are limited. The current study aimed at assessing the prevalence of HIV-1 DRMs among naïve and treatment-experienced HIV-1-infected patients in Iran.

Methods: From April 2013 to September 2018, the HIV-1 protease and reverse transcriptase genes were amplified and sequenced in plasma specimens of 60 newly diagnosed antiretroviral-naive individuals and 46 participants receiving antiretroviral therapies (ARTs) for at least six months with an HIV viral load of more than 1000 IU/mL to determine the HIV-1 DRMs and subtypes.

Results: Among the 60 treatment-naïve HIV-1-infected participants, 8.3% were infected with HIV-1 variants with surveillance DRMs (SDRMs). The SDRMs, D67N and D67E, belonged to the NRTIs class in two patients and K103N and V106A belonged to the NNRTIs class in three patients. The phylogenetic analysis showed that 91.7% of the subjects were infected with subtype CRF35_AD, followed by subtype B (5.0%) and CRF01_AE (3.3%). Among the 46 ART-experienced participants, 33 (71.7%) carried HIV-1 variants with SDRMs (9.1% against PIs, 78.8% against NRTIs, and 100% against NNRTIs). M46I and I47V were the most common mutations for PIs, M184V was the most common mutation for the NRTIs, and K103N/S was the most common mutation for NNRTIs. Phylogenetic analysis of the polymerase region showed that all of the 46 HIV-1-infected patients who failed on ART carried CRF35_AD.

Conclusions: The moderate prevalence of SDRMs (8.3%) in treatment-naïve and ART-failed (77.1%) Iranian patients with HIV-1-infection emphasizes the need for systematic viral load monitoring, expanding drug resistance testing, carefully surveilling individuals on ART regimens, and facilitating access to new antiretrovirals by health authorities.

Fig 1. Phylogenetic tree was dawned using MEGA7 software based on HIV-1 protease and reverse transcriptase nucleotide sequences (1015 bp) obtained from plasma samples of 60 treatment-naïve Iranian patients with HIV-1 infection and those corresponding to various HIV subtypes/CRFs obtained from the GenBank HIV database.

The Phylogenetic tree was constructed using the neighbor-joining method; the bootstrap values over 70% obtained after 1000 replicates are also shown.

Fig 2. Phylogenetic tree was dawned using MEGA7 software based on HIV-1 protease and reverse transcriptase nucleotide sequences (1015 bp) obtained from plasma samples of 46 treatment-experienced Iranian patients with HIV infection and those corresponding to various HIV subtypes/CRFs obtained from the GenBank HIV database.

The phylogenetic tree was constructed using the neighbor-joining method; the bootstrap values over 70% obtained after 1000 replicates are also shown.